1 / 11

OPTIMUS

OPTIMUS. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study.

benjamin
Télécharger la présentation

OPTIMUS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OPTIMUS Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Dominick J. Angiolillo, MD, PhD; Steven B. Shoemaker, MD; Bhaloo Desai, PhD; Hang Yuan, PhD; Ronald K. Charlton, PhD; Esther Bernardo, BSc; Martin M. Zenni, MD; Luis A. Guzman, MD; Theodore A. Bass, MD; Marco A. Costa, MD, PhD Published online in Circulation January 29, 2007

  2. OPTIMUS: Background • After treatment with clopidogrel, patients with type 2 diabetes mellitus have reduced platelet inhibition compared with patients who are not diabetic. • Recent studies have shown that type 2 diabetes mellitus patients have reduced response to P2Y12 receptor antagonists, including clopidogrel, compared with nondiabetic subjects. Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  3. OPTIMUS: Background (cont.) • The aim of this pilot study was to evaluate the impact of a high maintenance dose of clopidogrel on platelet function profiles in type 2 diabetes mellitus patients with coronary artery disease (CAD) on long-term dual antiplatelet therapy who demonstrate suboptimal platelet inhibition. Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  4. OPTIMUS: Study Design 40 patients > 18 years with type 2 diabetes mellitus and coronary artery disease All patients also received aspirin (81 mg daily). Prospective. Randomized. Parallel-Group. R Group A 75 mg of Clopidogrel 30 days,n=20 Group B 150 mg of Clopidogrel 30 days, n=20 Platelet Function Testing Platelet Function Testing 75 mg of Clopidogrel 30 days n=20 75 mg of Clopidogrel 30 days n=20 Platelet Function Testing At 60 days • Primary Endpoint: Maximal ADP-induced platelet aggregation Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  5. OPTIMUS: Demographics *IDDM = Insulin-dependent diabetes mellitus; †NIDDM = Non-insulin-dependent diabetes mellitus; ±HbA1-C = hemoglobin A1C Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  6. OPTIMUS: Demographics (Cont.) Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  7. OPTIMUS Trial: Primary Endpoint Study Time Point 2: Maximal ADP-Induced (20 µmol/L) Platelet Aggregation p = 0.002 • Platelet aggregation was significantly reduced in the 150mg group compared with the 75mg group (63.1% vs. 52.3%, p=0.002) (%) n = 20 n = 20 Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  8. OPTIMUS Trial: Results Late Adenosine Diphosphate Induced (20 µmol/L) Platelet Aggregation • At one month, patients assigned to the 150mg clopidogrel maintenance dose had an approximate 15% reduction in late (5 minutes) platelet aggregation after stimulus with 20 µmol/L ADP p <0.0001 (%) n = 20 n = 20 Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  9. OPTIMUS Trial: Results Study Time Point 3: Maximal ADP-Induced Platelet Aggregation (20µmol/L) p=0.55 p=0.97 • Patients assigned to 150mg dose returned to values comparable to those at baseline after a switch back to standard dosing (75mg) (%) n = 20 n = 20 n = 20 n = 20 Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  10. OPTIMUS: Limitations • The study did not account for performance of multiple significance tests or for potential correlation among various measures of platelet function. • This study was also not powered to evaluate the risk of bleeding with the use of high-dose clopidogrel in association with aspirin. • The study was not designed to measure clinical outcomes and therefore the results are exploratory and should not be applied to clinical practice. Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

  11. OPTIMUS: Summary • This study demonstrates that the current recommended maintenance dose of clopidogrel is associated with a high incidence of suboptimal response for patients with type 2 diabetes mellitus and coronary artery disease. • Though some patients continued to show high platelet aggregation levels despite increased doses of clopidogrel, the study showed the overall biological effectiveness of a 150mg maintenance dose regimen compared with standard doses of 75mg in high risk patients Angiolillo, et al. Circulation. 2007 Jan; 115: 708-716.

More Related